Version 1
: Received: 20 September 2023 / Approved: 21 September 2023 / Online: 25 September 2023 (04:39:59 CEST)
How to cite:
Gimenes Lima, G.; Da Costa, H.H.M.; Prudencio, C.R.; Portilho, A.I.; De Gaspari, E. RBD-Adjuvanted Preparation: Evaluation of IgG and IgM Antibodies for One Year and Cross-Reactivity with Omicron Variant in Mice. Preprints2023, 2023091613. https://doi.org/10.20944/preprints202309.1613.v1
Gimenes Lima, G.; Da Costa, H.H.M.; Prudencio, C.R.; Portilho, A.I.; De Gaspari, E. RBD-Adjuvanted Preparation: Evaluation of IgG and IgM Antibodies for One Year and Cross-Reactivity with Omicron Variant in Mice. Preprints 2023, 2023091613. https://doi.org/10.20944/preprints202309.1613.v1
Gimenes Lima, G.; Da Costa, H.H.M.; Prudencio, C.R.; Portilho, A.I.; De Gaspari, E. RBD-Adjuvanted Preparation: Evaluation of IgG and IgM Antibodies for One Year and Cross-Reactivity with Omicron Variant in Mice. Preprints2023, 2023091613. https://doi.org/10.20944/preprints202309.1613.v1
APA Style
Gimenes Lima, G., Da Costa, H.H.M., Prudencio, C.R., Portilho, A.I., & De Gaspari, E. (2023). RBD-Adjuvanted Preparation: Evaluation of IgG and IgM Antibodies for One Year and Cross-Reactivity with Omicron Variant in Mice. Preprints. https://doi.org/10.20944/preprints202309.1613.v1
Chicago/Turabian Style
Gimenes Lima, G., Amanda Izeli Portilho and Elizabeth De Gaspari. 2023 "RBD-Adjuvanted Preparation: Evaluation of IgG and IgM Antibodies for One Year and Cross-Reactivity with Omicron Variant in Mice" Preprints. https://doi.org/10.20944/preprints202309.1613.v1
Abstract
This study continued the analysis of immunization with the receptor binding domain (RBD) associated with the adjuvants Dimethyldioctadecylammonium bromide (DDA) and Saponin (Sap) (RBD+DDA/Sap) or Aluminum hydroxide (AH) and outer membrane vesicles (OMVs) of Neisseria meningitidis (RBD+AH/OMV); from adult to old age and assessed maternal-fetal transference of antibodies. Outbred Swiss mice were immunized with 2 intramuscular (IM) doses with the antigenic preparations RBD+DDA/Sap, RBD+AH/OMV or RBD alone. The humoral immune response was evaluated using ELISA, avidity-ELISA, Immunoblotting and a Omicron-surrogate-neutralization assay (BA.1), while the cellular immune response was analyzed by ELISpot. Our previous work studied the IgG response; here, we verified that IgM levels were higher right after the immunization doses, but, as IgG, it persisted until 368 days after the immunization. The avidity of IgM increased from low to intermediate-to-high after the booster dose. RBD+DDA/Sap presented neutralizing indexes against Omicron at days 47 and 176, while RBD+AH/OMV showed neutralization on days 21, 47 and 176. Cellular response, measured 465 days after immunization, revealed IFN-Y and IL-4 secretion. The offspring of RBD+DDA/Sap had detectable antibodies, which decreased around 45 days after birth, the last point we analyzed. The results suggested that DDA/Sap is a promising adjuvant mixture to enhance humoral and cellular immune response against SARS-CoV-2, improving maternal-fetal transference of antibodies; cross-reactivity with Omicron variant; and the maintenance of antibodies for a long period.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
